Melanoma future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anum Ijaz M.B.B.S., M.D.[2]
Future Techniques
Future Techniques
- Optical Coherence Tomography (OCT)
In addition to identifying high-risk patients, researchers also want to identify high-risk lesions within a given patient. Many new technologies, such as optical coherence tomography (OCT), are being developed to accomplish this. OCT allows pathologists to view 3-D reconstructions of the skin and offers more resolution than past techniques could provide. In vivo confocal microscopy and fluorescently tagged antibodies are also proving to be valuable diagnostic tools.
- Tumor-informed circulating DNA (ctDNA) Assay
Small cohort studies demonstrate that ctDNA positivity may predict relapse, detected either on imaging (radiographic) or by symptoms and exam (clinical). [1]. Ongoing studies are evaluating whether ctDNA can detect early relapse in resected melanoma, identifying molecular recurrence (tumor DNA in blood before clinical or radiographic evidence) to guide earlier treatment. [3]
References
References
- ↑ Eroglu Z, Krinshpun S, Kalashnikova E, Sudhaman S, Ozturk Topcu T, Nichols M, Martin J, Bui KM, Palsuledesai CC, Malhotra M, Olshan P, Markowitz J, Khushalani NI, Tarhini AA, Messina JL, Aleshin A (June 2023). “Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients”. Cancer. 129 (11): 1723–1734. doi:10.1002/cncr.34716. PMID 36869646 Check
|pmid=value (help).
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH